Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. ESMO Videos
  3. Head and Neck Cancer Videos

Eftilagimod Alpha (Soluble LAG-3) Plus Pembrolizumab versus Pembrolizumab in First-Line Recurrent or Metastatic HNSCC with CPS ≥1

Breaking Science in Head and Neck Cancer Video Series

Login to get immediate access to this content.

Login

Speaker: Claus Andrup Kristensen, Denmark

Abstracts discussed:

  • LBA35 - Primary Results from TACTI-003: A Randomized Phase IIb Trial Comparing Eftilagimod Alpha (soluble LAG-3) Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with CPS ≥1: Watch the presentation from ESMO 2024 now

The speakers and studies featured in this video series were selected independently by ESMO.

Published October 2024

Related Videos

Screenshot Domenica LORUSSO
Screenshot Minke LUCAS
Screenshot Suresh SENAN
Screenshot Peter DE GOOYER

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.